LAVAL, QC / ACCESS Newswire / October 9, 2025 / Bausch Health Companies Inc. (the "Company") (NYSE:BHC)(TSX:BHC) today announced the results of the special meeting of shareholders held on October 7, 2025 (the "Shareholders Meeting"). At the Shareholders Meeting, shareholders of the Company approved the ratification, confirmation and approval of the adoption of the Company's Amended and Restated Shareholder Rights Plan Agreement dated April 14, 2025, as amended and restated on August 25, 2025 (the "Rights Pl ...

LAVAL, QC / ACCESS Newswire / September 30, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release third quarter 2025 financial results after market close on Wednesday, October 29, 2025. Bausch Health will host a live conference call and webcast at 5:00 p.m. ...

Designed for dental professionals, OraTalks connects leading voices with insights to spark meaningful dialogue. Nine-episode inaugural season hosted by industry thought leader Melissa K. ...

Core Thesis - Bausch Health Companies Inc. (BHC) is viewed positively despite significant share price decline, with a current trading price of $7.25 and trailing and forward P/E ratios of 27.88 and 1.76 respectively [1][2] Company Overview - BHC is a diversified healthcare company involved in pharmaceuticals and medical devices, with operations in eye care, gastroenterology, neurology, dermatology, and aesthetics [2] - The company has experienced an 80% decline in share price since July 2021, attributed to higher interest rates, policy uncertainty, and post-COVID overcapacity [2] Financial Performance - BHC generates stable cash flows with a five-year revenue CAGR of 3.5%, LTM EBITDA margins of 31.5%, and a free cash flow yield of 35.8% [3] - The company has a significant leverage issue, with $20 billion in net debt against $3.1 billion in EBITDA, leading to steep discounts of 66.5% on TEV/EBITDA and 31.5% on TEV/sales compared to peers [3] Recent Developments - The 2022 spin-off of Bausch + Lomb (BLCO) resulted in a $630 million debt reduction, and BHC retains an 87.5% stake in BLCO valued at $4.8 billion, nearly double its market cap [3] - A $6 billion maturity wall is due in 2028, and the 2029 patent expiry of the $1.9 billion IBS drug Xifaxan is raising solvency concerns [4] Market Sentiment and Risks - A recent acquisition by Paulson Capital of a 34 million-share block at a 19.8% premium indicates potential asset monetization, which could help in deleveraging [4] - Scenario modeling suggests a 39% probability of bankruptcy versus a 20% chance of significant gains, indicating a highly asymmetric risk/reward profile [5]

In this article, we will be taking a look at the 12 Cheap Healthcare Stocks to Buy Now. Bausch Health Companies is one of them. Bausch Health Companies Inc. (NYSE:BHC), a global specialty pharmaceutical company, has recently gained attention as an undervalued player in healthcare due to strategic acquisitions and pipeline developments rather than financial trends alone. The company focuses on areas including eye health, gastroenterology, hepatology, neurology, and dermatology. It is among the cheap health ...

Bausch Health Companies Inc. stands as a prominent player in Canada’s pharmaceutical and medical-device landscape, operating a diversified portfolio that spans eye health, gastroenterology, dermatology, neurology and aesthetic devices. Headquartered in Laval, Quebec, the company combines legacy brands with specialty product lines such as Bausch + Lomb eye-care solutions and gastroenterology offerings under the Salix Pharmaceuticals unit. Over the last decade Bausch Health has navigated complex restructuring ...

Group 1 - The article discusses the author's extensive experience in the investment banking sector, highlighting a focus on equity analysis and sector research [1] - The author emphasizes the importance of understanding the narratives behind financial statements, indicating a deep analytical approach to investment [1] - The author is currently developing an investment project targeting the CIS region, aiming to apply Western analytical tools to identify hidden value in emerging markets [1] Group 2 - The article does not provide specific company or industry data, focusing instead on the author's background and investment philosophy [2]

Accessibility StatementSkip Navigation The transaction adds larsucosterol, an FDA Breakthrough Therapy for alcohol-associated hepatitis with a registrational Phase 3 clinical trial in development, to Bausch Health's hepatology pipeline LAVAL, QC, and CUPERTINO, Calif., Sept. 11, 2025 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC) ("Bausch Health"), a global, diversified pharmaceutical company, today announced the successful completion of its previously announced tender offer to acquir ...

It has been about a month since the last earnings report for Bausch Health (BHC) . Shares have added about 21.4% in that time frame, outperforming the S&P 500.But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Bausch due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.Bausch Health’s ...

Group 1 - The average returns from public articles show a significant increase, with 2023 at 8.4%, 2022 at 6.9%, and 2021 at 29.9% [2] - The flagship products include "Top DIY Picks" which focus on undervalued stocks with upcoming catalysts, "Dividend-income Champs" with a history of dividend growth, and "DIY Risky Picks" aimed at speculative allocations [2] Group 2 - The investing group DIY Value Investing shares stock picks that are undervalued and have potential catalysts for upside [1] - The group also provides recommendations for dividend-income stocks along with a payment calendar and quantitative tracking [1]